Wolverine Blend
Wolverine Blend, a peptide. Market name for BPC-157 and TB-500 sold in one vial for injury recovery, the pairing being justified by two unrelated proposed mechanisms…
Market name for BPC-157 and TB-500 sold in one vial for injury recovery, the pairing being justified by two unrelated proposed mechanisms — VEGF upregulation and nitric-oxide pathway modulation for the pentadecapeptide, G-actin sequestration and cell migration for the thymosin fragment. The name is a nickname rather than an acronym, and the combination has essentially no evidence: the one controlled animal test of the pair found no additive benefit over either peptide alone.
COMPOSITION IS FROM VENDOR PAGES, NAMED AS SUCH, because there is no other source. The 1:1 split is stated consistently — royal-peptides.com "Each vial contains a total of 20 mg of research material: 10 mg BPC-157 and 10 mg TB-500", oathresearch.com "BPC-157 (5mg) and TB-500 (5mg) in a balanced 1:1 ratio, totaling 10mg", pspeptides.com "10mg BPC-157 + 10mg TB-500 (20mg vial) or 5mg + 5mg (10mg vial)", plus americanpeptides.us and prohealthsolutionsfl.com. A COMPOUNDED ROUTE DIVERGES: moonshotmp.com states "roughly 5mg BPC-157 and 10mg TB-500 per vial", i.e. 1:2, so a user's actual ratio depends on where it came from. THE DOSE BLOCK IS EMPTY ON PURPOSE. Every source states a VIAL TOTAL, not a per-injection amount; a vial is reconstituted and split across many doses, so storing 20 mg as a dose would overstate a single administration by an order of magnitude. EVIDENCE FOR THE COMBINATION, such as it is: PMID:42542926 is the only controlled test, a rat Achilles model with four arms including "combined BPC-157 + TB-500", administered intraperitoneally for four weeks at 10 and 60 micrograms/kg/day — a 1:6 ratio, not the vendor 1:1 — and its finding is negative, "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone". PMID:34324435 is a retrospective chart review in which "The other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4", uncontrolled, with "No specific tools ... used to measure their improvement" and separate injections rather than a blend. No indexed paper studies a branded blend or a vendor ratio, and "Wolverine" never appears in PubMed beside these peptides.
Sources: PMID:42542926, PMID:34324435